Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Liposomal Encapsulation Of Azidothymidine Results In Decreased Hematopoietic Toxicity And Enhanced Activity Against Murine Acquired Immunodeficiency Syndrome.
N. Phillips, C. Tsoukas
Published 1992 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
This study has determined the effect of liposomal encapsulation on the hematopoietic toxicity and antiviral activity of 3'-azido-3'-deoxythymidine (AZT) in mice. Daily intravenous administration in the dose range 0.4 to 10 mg/kg body weight for 5 days significantly depressed bone marrow cellularity with a corresponding decrease in red blood cell, blood neutrophil, and monocyte numbers. Maximum toxicity was seen at 2 mg/kg or greater. Liposomal encapsulation of AZT and administration at 2 mg/kg abrogated the toxicity of AZT. The neutrophil inflammatory response to thioglycollate injected intraperitoneally was significantly inhibited by AZT at all doses, whereas liposomal AZT was without effect. The inhibitory activity of AZT against Concanavalin A (Con A)-stimulated splenic lymphocyte proliferation in vitro was reduced on liposomal encapsulation of AZT, while treatment of mice with liposomal AZT but not free AZT resulted in a significant reduction of Con A-stimulated proliferation. Liposomal AZT was more effective than AZT in preventing the development of plasma reverse transcriptase activity and the depletion of Thy 1.2(+)-L3T4+ T cells after infection of mice with LP-BM5 retrovirus. These results indicate that AZT-induced hematopoietic toxicity may not be a limiting factor for antiviral therapy, and that the use of liposomes to deliver AZT results in enhanced antiretroviral activity in mice.
This paper references
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
R. Dornsife (1991)
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection
PA Pizzo (1988)
The liposome-mediated macrophage suicide technique
N. Vanrooijen (1989)
Reversible agranulocytosis related to azidothymidine therapy
J. Goldsmith (1989)
Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains.
J. Hartley (1989)
Nussinoff-Lehrman S: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex
DD Richman (1987)
Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine
R. Ruprecht (1986)
The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
D. Stambuk (1989)
Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
N. Phillips (1987)
Cessation of zidovudine therapy may lead to increased replication of HIV-1.
M. Wainberg (1989)
Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer.
G. López-Berestein (1984)
The liposome-mediated macrophage 'suicide' technique.
N. van Rooijen (1989)
Nature, time course and dose dependence of zidovudine‐related side effects: results from the Multicenter Canadian Azidothymidine Trial
K. Gelmon (1989)
Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.
A. Rahman (1985)
Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
N. Phillips (1985)
Reversal of azidothymidine-induced bone marrow suppression by 2',3'-dideoxythymidine as studied by hemopoietic clonal culture.
Y. Yoshida (1990)
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
P. Furman (1986)
EFFECTS OF ZIDOVUDINE IN 365 CONSECUTIVE PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
E. Dournon (1988)
A selective signaling defect in helper T cells induced by antigen-presenting cells from mice with murine acquired immunodeficiency syndrome.
T. Mizuochi (1990)
Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously.
I. Fidler (1985)
Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS.
D. Portnoi (1990)
Abrogation of resistance to severe smallpox in C57BL/6 mice infected with LP-BM5 virus
RML Buller (1987)
Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice
F. P. Chow (1991)
3'-Azido-3'-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening.
H. Ohnota (1990)
Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
E. Herman (1983)
Liposome-encapsulated doxorubicin. Preliminary results of phase-I and phase-I1 trials, in Lopez-Berestein G, Fidler IJ: (eds): Liposomes in the Therapy of Infectious Diseases and Cancer
J Treat (1989)
Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS).
P. Gill (1987)
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
G. López-Berestein (1987)
A unique subset of normal murine CD4+ T cells lacking Thy‐1 is expanded in a murine retrovirus‐induced immunodeficiency syndrome, MAIDS
K. Holmes (1990)
Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections.
R. Mehta (1987)
The efficacy of azidothymidine ( U T ) in the treatment of patients with AIDS and AIDSrelated complex. A double-blind, placebo-controlled trial
S Segreti (1987)
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
D. Baltimore (1970)
Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice
D. E. Mosier (1985)
The spleen in HIV infection--morphological evidence of HIV-associated macrophage dysfunction.
S. Falk (1990)
PS: Pharmacological, toxicological and therapeutic evaluation of doxorubicin entrapped in cardiolipin liposomes
A Rahman (1985)
Morse HC 111: Contribution of helper T cells to the pathogenesis of murine AIDS
Susceptibility to a mouse acquired immunodeficiency syndrome is influenced by theH-2
Diane Hamelin-Bourassa (2006)
ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
R. Yarchoan (1986)
Role of heme metabolism in AZT‐induced bone marrow toxicity
J. Lutton (1990)
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection.
M. S. Meltzer (1990)
Immunoliposome targeting to CD4+ cells in human blood.
N. Phillips (1990)
Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes.
J. Szebeni (1990)
Human immunodeficiency virus causes mononuclear phagocyte dysfunction.
G. Baldwin (1990)
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
G. G. Jackson (1988)
Drug-carrier potential of liposomes in cancer chemotherapy.
G. Gregoriadis (1974)
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
D. Richman (1987)
Contribution of helper T cells to the pathogenesis of murine AIDS
DE Mosier (1988)
Characteristics of B cell proliferation and activation in murine AIDS.
D. Klinman (1989)
Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model.
T. Basham (1990)
Azidothymidine inhibits mitogen stimulated growth and DNA-repair in human peripheral lymphocytes.
B. Munch-Petersen (1988)
This paper is referenced by
LIPOSOMAL DRUG DELIVERY SYSTEM FOR ZIDOVUDINE: DESIGN ANDCHARACTERIZATION
Bhambere Deepak Sunil (2010)
Nanotechnology and the Treatment of HIV Infection
R. Parboosing (2012)
Nanotechnology and HIV: potential applications for treatment and prevention.
P. Kim (2010)
An Introduction to the Approaches of Novel Drug Delivery Systems for Acquired Immune Deficiency Syndrome (AIDS)
N. Singh (2016)
FORMULATION AND CHARACTERIZATION OF VESICULAR DRUG DELIVERY SYSTEM FOR ANTI-HIV DRUG
R. Doijad (2009)
Exploring the Nanotechnology-Based Drug Delivery Systems for AIDS Treatment
F. Carvalho (2011)
Formation de liposomes par un procédé innovant utilisant les fluides supercritiques
L. Lesoin (2011)
Liposomal formulation of alpha-tocopheryl maleamide: in vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice.
J. Turánek (2009)
Magnetic nanoformulation of azidothymidine 5’-triphosphate for targeted delivery across the blood–brain barrier
Z. Saiyed (2010)
Optimization of nanostructured lipid carriers for Zidovudine delivery using a microwave‐assisted production method
S. M. Cavalcanti (2018)
Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid.
J. Drach (1993)
Lymphatic targeting of zidovudine using surface-engineered liposomes
C. D. Kaur (2008)
Long Acting Injections and Implants
J. Wright (2012)
DESENVOLVIMENTO DE NANOPARTÍCULAS DE PLA E PLA-PEG PARA ADMINISTRAÇÃO INTRANASAL DE ZIDOVUDINA
R. Mainardes (2007)
Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles of Zidovudine in Rats
Shah Purvin (2014)
Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection.
A. Désormeaux (1998)
Treatment of Visceral Leishmaniasis with Sterically Stabilized Liposomes Containing Camptothecin
M. Proulx (2001)
Nanotecnología y microbicidas: protección frente a la infección por VIH
J. S. Rodríguez (2012)
Progress in antiretroviral drug delivery using nanotechnology
R. Mallipeddi (2010)
Retinoic Acid trans Acute Promyelocytic Leukemia Cells by Liposomal All-Induction of Differentiation in Myeloid Leukemia Cell Lines and Updated
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites
Tushar K Vyas (2006)
Exploring the use of novel drug delivery systems for antiretroviral drugs.
E. Ojewole (2008)
Novel Prospective Treatment Options
J. Stanley (2015)
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics
M. Dobrovolskaia (2015)
Targeting of 3′-Azido 3′-Deoxythymidine (AZT)-Loaded Poly(Isohexylcyanoacrylate) Nanospheres to the Gastrointestinal Mucosa and Associated Lymphoid Tissues
Assia Dembri (2004)
Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?
S. Gurunathan (2020)
Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.
A. Bender (1996)
HIV-1: identification of a pathway for virus release and development of a new nanotechnological strategy to counteract the infection
Andrea Gramatica (2014)
The effect of Nanoliposomal and PE Gylated Nanoliposomal Forms of 6- Gingerol on Breast Cancer Cells
M. Khalili (2013)
Nanotechnology-based systems for the treatment and prevention of HIV/AIDS.
J. das Neves (2010)